Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Susan M. Stalnecker Named to Bioventus Board of Managers

Bioventus
Posted on: 25 Oct 18

Bioventus, a global leader in orthobiologic solutions, today announced the appointment of Susan M. Stalnecker, former Vice President and Treasurer, E.I. du Pont de Nemours and Company, to the company’s Board of Managers, replacing Michael Minogue.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181025005071/en/

Susan M. Stalnecker, New Member Bioventus Board of Managers (Photo: Business Wire)

“Susan is joining the Bioventus Board at an exciting time as we accelerate the growth of our osteoarthritis business, expand our surgical orthobiologics business and continue to launch our products in new international markets like Brazil,” said Tony Bihl, CEO of Bioventus. “Her global financial background, experience leading audit and finance committees and leadership roles on both public company and nonprofit boards will provide us with fresh perspectives and insights to help drive our strategy to be a global leader in orthobiologics.”

“The orthobiologic space intrigues me and I believe I can help the team at Bioventus achieve their goals of bringing more solutions to market to help patients heal and return to active lifestyles,” said Stalnecker. “Clinicians and spine surgeons around the world are noticing this company and its innovations, and I am eager to guide Bioventus as it continues to grow into these markets.”

Stalnecker served as Vice President of E. I. du Pont de Nemours and Company until she retired in 2016. During her nearly 40-year career at DuPont she served in several senior leadership roles including Vice President, Treasurer & M&A Vice President, Risk Management; Vice President-Government and Consumer Markets; and, Vice President Productivity & Shared Services.

Stalnecker served on the Board of trustees of Duke University from 2003 to 2015, and as Vice Chair from 2003-2005. She currently serves on the Board of Directors of Leidos Holdings, Inc., Board of Trustees, Optimum Fund Trust and the Board of Trustees, Duke Health System. In addition, she was a Board Director of PPL Corporation. She is also a Senior Adviser, Boston Consulting Group.

She received a bachelor’s degree from Duke University and an MBA from the Wharton School of Graduate Business at the University of Pennsylvania.

About Bioventus

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.

Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181025005071/en/

Business Wire
www.businesswire.com

Last updated on: 25/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.